irinotecan hydrochloride 20 mg/ml concentrate for soln for inf
actavis group hf - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - other antineoplastic agents
irinotecan teva
abic marketing ltd, israel - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan - * for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. * for the treatment of patients with small cell lung cancer.* for the treatment of patients with gastric cancer.* irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.
hospira irinotecan hydrochloride trihydrate trihydrate for injection 40mg/2ml vial
hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan indicated for the treatment of advanced colorectal cancer. -in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced cancer -as a single agent in patients who have failed 5-fluorouracil containing treatment regimen.
irinotesin 500mg/25ml irinotecan hydrochloride trihydrate 500mg/25ml concentrated injection vial
medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: sorbitol; lactic acid; sodium hydroxide; hydrochloric acid; water for injections - indicated as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy
irinotecan hydrochloride trihydrate injection solution
sandoz canada incorporated - irinotecan hydrochloride - solution - 20mg - irinotecan hydrochloride 20mg - antineoplastic agents
irinotecan intas irinotecan hydrochloride trihydrate 500 mg/25 ml concentrated injection vial
accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: sorbitol; hydrochloric acid; sodium hydroxide; water for injections; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan intas irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial
accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan hydrochloride- irinotecan hydrochloride injection
heritage pharmaceuticals inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - - irinotecan hydrochloride injection, usp is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection, usp is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9)] irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. in separate studies in rats, this dose produced an irinote
irinotecan hydrochloride injection usp solution
accord healthcare inc - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents
irinotecan hydrochloride injection, usp solution
generic medical partners inc - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) - solution - 20mg - irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20mg - antineoplastic agents